Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs

Author：          

Publisher： Spandidos Publications

ISSN： 1107-3756

Source： International Journal of Molecular Medicine, Vol.29, Iss.1, 2012-01, pp. : 102-106

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma

By  

Acta Haematologica, Vol. 134, Iss. 1, 2015-04 ,pp. : 25-31

Karger

Access to resources Recommend Favorite

Proteasome Inhibition: Novel Therapy for Multiple Myeloma

By  

Oncology Research and Treatment, Vol. 29, Iss. 4, 2006-03 ,pp. : 162-168

Karger

Access to resources Recommend Favorite

Effects of the proteasome inhibitor, bortezomib, on cytodifferentiation and mineralization of periodontal ligament cells

By  

JOURNAL OF PERIODONTAL RESEARCH, Vol. 50, Iss. 2, 2015-04 ,pp. : 248-255

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib-Induced Rhabdomyolysis in Multiple Myeloma

By  

Acta Haematologica, Vol. 116, Iss. 3, 2006-10 ,pp. : 203-206

Karger

Access to resources Recommend Favorite

Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 2, 2018-01 ,pp. : 271-275

John Wiley & Sons Inc

Access to resources Recommend Favorite